Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.
Anemia|Non-Myeloid Malignancies
DRUG: Darbepoetin alfa|DRUG: Placebo
Incidence of red blood cell (RBC) transfusion from week 5 to End of Treatment Period (EOTP), from week 5 to EOTP
Incidence of achieving a hemoglobin concentration of greater than or equal to 11 g/dL in the absence of RBC transfusions in the preceding 28 days from week 5 to EOTP, from week 5 to EOTP|Number of RBC transfusions from week 5 to EOTP, from week 5 to EOTP|Change in FACT-Fatigue subscale score from baseline to EOTP, from baseline to EOTP|Change in FACT-G Physical Well-being subscale from baseline to EOTP, from baseline to EOTP|Incidence and severity of adverse events, throughout study|Incidence of hemoglobin concentration greater than 13.0 g/dL at any time on study, at any time on study|Change in FACT-G total score from baseline to EOTP, from baseline to EOTP|Incidence of an increase in hemoglobin concentration greater than or equal to 2 g/dL in a 28-day window and any negative clinical consequences, throughout study|Change in EQ-5D Thermometer from baseline to EOTP, from baseline to EOTP|Change in BSI Anxiety scale score from baseline to EOTP, from baseline to EOTP|Change in BSI Depression scale score from baseline to EOTP, from baseline to EOTP|Change in number of caregiver hours from baseline to EOTP, from baseline to EOTP|Incidence of a confirmed antibody formation to darbepoetin alfa, throughout study
The purpose of this study is to compare the effect of darbepoetin alfa against placebo for the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle chemotherapy.